Grant: Discovery Grants Program - Individual
The University of Western Ontario
$33,000.00
Retrobiosynthesis of privileged pharmaceutical scaffolds from non-standard amino acids
FY 2024-25
Summary
Natural product pharmaceuticals have traditionally been manufactured using direct extraction from plants or through total chemical synthesis. Despite these successes, total chemical synthesis has been unable to access many complex chiral natural products, while plants are slow-growing, difficult to engineer, and are susceptible to numerous environmental threats. Microbial synthesis, in which natural product pathways are reconstructed in common laboratory microorganisms, overcomes limitations of both crop-based manufacturing and total chemical synthesis.
For the past six years, my research direction has focused on the discovery, reconstruction, and optimization of natural product pathways in diverse microorganisms. From this work, I devised a novel pathway for synthesizing diverse alkaloid structures from simple amino acids building blocks. For the proposed research, I leveraged our alkaloid synthesis scheme to access an array of privileged pharmaceutical scaffolds involved in the synthesis of natural and semi-synthetic pharmaceuticals. Pharmaceuticals targeted in the proposed research are the anesthetic ephedrine (phenylpropylamino alkaloids), the anti-inflammatory colchicine (phenethylisoquinoline alkaloids), and solifenacin (phenylisoquinoline alkaloids), a semi-synthetic drug used to treat overactive bladder.
Over the next five years, my research program will design, construct, and optimize the proposed retrosynthetic pathways in engineered yeast. We will initiate this work by demonstrating synthesis of the proposed drug scaffolds from supplemented amino acids. We will improve alkaloid production using both rational metabolic engineering and random strain evolution techniques. Installing pathways for de novo synthesis of non-standard amino acids will enable synthesis of privileged pharmaceutical scaffolds directly from sugar. Having demonstrated synthesis of dedicated pharmaceutical scaffolds, we will functionalize scaffolds to commercial natural product drugs using the anti-inflammatory colchicine as proof-of-concept by sourcing and implementing enzymes from the flame lily and autumn crocus. Colchicine production will be investigated and optimized in a controlled bioreactor process.
The proposed research will provide a more efficient, scalable, and reliable supply of plant-based and semi-synthetic medicines, as microbes can be cultivated in large-scale bioreactors in mere days compared to many months using traditional modes of pharmaceutical manufacturing. Finally, the proposed research program will also provide trainees with a broad array of skills in synthetic biology, bioinformatics, metabolic engineering, and chemical biology, thus preparing them for diverse careers in the natural sciences and engineering.
Program
Discovery Grants Program - Individual
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
RGPIN-2023-04542
Name nom
Pyne, Michael
Department département
Biology
Organization id
36
Institution établissement
The University of Western Ontario
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2024
Competition year année de concours
2023
Award amount
33000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
DISCOVERY RESEARCH
Group fr
RECHERCHE AXÉE SUR LA DÉCOUVERTE
Committee code
1501
Committee name en
Genes, Cells and Molecules
Committee name fr
Gènes, cellules et molécules
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
5408
Research subject group en
Biochemistry
Research subject group fr
Biochimie
Research subject en
Metabolism
Research subject fr
Métabolisme
Field of research list names en
Not available
Field of research list names fr
Non disponible
Socioeconomic objective list names en
Not available
Socioeconomic objective list names fr
Non disponible
Application title
Retrobiosynthesis of privileged pharmaceutical scaffolds from non-standard amino acids
Keywords
biosynthesis; natural product; yeast; colchicine; alkaloid; metabolic engineering; synthetic biology; crispr; retrosynthesis; amino acid
Application summary
Natural product pharmaceuticals have traditionally been manufactured using direct extraction from plants or through total chemical synthesis. Despite these successes, total chemical synthesis has been unable to access many complex chiral natural products, while plants are slow-growing, difficult to engineer, and are susceptible to numerous environmental threats. Microbial synthesis, in which natural product pathways are reconstructed in common laboratory microorganisms, overcomes limitations of both crop-based manufacturing and total chemical synthesis.
For the past six years, my research direction has focused on the discovery, reconstruction, and optimization of natural product pathways in diverse microorganisms. From this work, I devised a novel pathway for synthesizing diverse alkaloid structures from simple amino acids building blocks. For the proposed research, I leveraged our alkaloid synthesis scheme to access an array of privileged pharmaceutical scaffolds involved in the synthesis of natural and semi-synthetic pharmaceuticals. Pharmaceuticals targeted in the proposed research are the anesthetic ephedrine (phenylpropylamino alkaloids), the anti-inflammatory colchicine (phenethylisoquinoline alkaloids), and solifenacin (phenylisoquinoline alkaloids), a semi-synthetic drug used to treat overactive bladder.
Over the next five years, my research program will design, construct, and optimize the proposed retrosynthetic pathways in engineered yeast. We will initiate this work by demonstrating synthesis of the proposed drug scaffolds from supplemented amino acids. We will improve alkaloid production using both rational metabolic engineering and random strain evolution techniques. Installing pathways for de novo synthesis of non-standard amino acids will enable synthesis of privileged pharmaceutical scaffolds directly from sugar. Having demonstrated synthesis of dedicated pharmaceutical scaffolds, we will functionalize scaffolds to commercial natural product drugs using the anti-inflammatory colchicine as proof-of-concept by sourcing and implementing enzymes from the flame lily and autumn crocus. Colchicine production will be investigated and optimized in a controlled bioreactor process.
The proposed research will provide a more efficient, scalable, and reliable supply of plant-based and semi-synthetic medicines, as microbes can be cultivated in large-scale bioreactors in mere days compared to many months using traditional modes of pharmaceutical manufacturing. Finally, the proposed research program will also provide trainees with a broad array of skills in synthetic biology, bioinformatics, metabolic engineering, and chemical biology, thus preparing them for diverse careers in the natural sciences and engineering.